What's new

Human medicines European public assessment report (EPAR): Xbryk, denosumab, Date of authorisation: 12/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Xbryk, denosumab, Date of authorisation: 12/02/2025, Status: Authorised

Jun 16, 2025 - 15:05
 0
Human medicines European public assessment report (EPAR): Xbryk, denosumab, Date of authorisation: 12/02/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Xbryk, denosumab, Date of authorisation: 12/02/2025, Status: Authorised
Read More

Tags:

Previous Article

To prevent ovarian cancers, fallopian tube removal is on the rise

Next Article

Allergen products development for immunotherapy and allergy diagnosis in moderat...

Related Posts

EMEA-003333-PIP01-22

EMEA-003333-PIP01-22

Jun 10, 2025  0

Human medicines European public assessment report (EPAR): Clopidogrel TAD, clopidogrel, Date of authorisation: 23/09/2009, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

May 13, 2025  0

Human medicines European public assessment report (EPAR): Lyfnua, gefapixant, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

May 14, 2025  0